![]() |
|
|
Vol. 286, Issue 2, 1066-1073, August 1998
Department of Molecular Pharmacology, St. Jude Children's Research
Hospital, Memphis, Tennessee
We examined a panel of cell lines for the expression of the myogenic
proteins myoD and myogenin. High level expression of both proteins was seen in rhabdomyosarcoma (RMS). To determine whether
promoter elements from these genes could direct RMS cell-specific expression, we generated reporter constructs containing one or two
copies of the myoD enhancer coupled to the SV40
promoter. Transient transfection reporter assays confirmed the
selective expression of
-galactosidase (
-gal) in 8 RMS cell
lines. In contrast, very low expression from the myoD
enhancer/SV40 promoter was detected in four non-RMS cell lines. To
determine whether the hybrid promoter could elicit RMS-specific
cytotoxicity, a mammalian expression vector containing the herpes
simplex virus thymidine kinase (HSVtk) under control of
the hybrid myoD enhancer/SV40 promoter was constructed.
After electroporation into several cell lines, selective RMS cell kill
was observed after treatment with ganciclovir. These data suggest that
in vivo tumor-specific expression of
HSVtk from the myoD enhancer/SV40
promoter may provide an alternative to current chemotherapy.